Pfizer and Eli Lilly shares were largely unaffected after the firms announced positive results from a joint late-stage trial in patients with osteoarthritis pain.
The June 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The June 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Analysts at Jefferies have come up with a list of four pharmaceuticals stocks that may be good investments for a time of uncertainty in global markets.
Keep in mind that short sellers betting against big pharma are taking on an added risk. They have to pay out the ongoing high dividends on top of the cost of borrowing…
The top analyst upgrades, downgrades and other research calls from Friday include ConocoPhillips, Domino's Pizza, Eli Lilly, Occidental Petroleum, PayPal and Penn National Gaming.
It’s no surprise that it was only a matter of time before the usage and storage of big data and analytics would come to the health care sector, and many of the…
The May 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
This year marks the 54th annual meeting of the American Society of Clinical Oncology, the world’s largest clinical cancer conference.
Amgen shares saw a nice bump after the FDA on Thursday approved its preventive treatment of migraine in adults.
The April 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Eli Lilly released its most recent quarterly earnings report before the markets opened on Tuesday.
Chris Lange 24/7 Wall St. has put together a preview of AbbVie, Eli Lilly and some of the other top pharma and biotech companies reporting their latest quarterly results in the coming week.
Incyte and Eli Lilly will be under the microscope next week as the FDA will decide the fate of their rheumatoid arthritis treatment.
